Of the Field

CPHI Americas 2026

C

PHI Americas 2026 moves beyond the traditional trade show format to create a premium, content-first experience specifically centered around the contract development and manufacturing ecosystem. The event provides specialized focus on contract manufacturing partners, delivering programming, networking, and content with maximum relevance and business value to…

Visit the official site
48Voices
5Underwriters
11Exhibitors
8On the bill · sessions
58Companies · in total
§I

The Voices

Programmed at CPHI, in alphabetical order.
Aaron Dely
VP of Research & Development · PLD Pharma Services
Aaron Pitts
BusinessPA
Alejandro Córdova Motte
Supply Chain & Access Director · CANIFARMA
Amit Limaye
Director · Becton Dickinson & Company (BD)
Amy Turnquist
BIP
Anuji Abraham
Senior Director, Pharmaceutical Development · Altasciences
Brent Del Monte
Principal · BGR Group
Brian Beyer
Senior Manager · KPMG
Daniel Cohen
Managing Director, Global Head of Pharma Services · Morgan Stanley
Derek Booth
Supervisory Special Agent · US Secret Service
Devin Carsdale
Bristol Myers Squibb
Dwane Hahn
PAXXUS
Emily George
Account Executive, Customer Growth · EcoVadis
Giorgio Salciarini
Head of Sales- Technical Business Development · BSP Pharmaceuticals
Hassan Siddiqui
Boston Consulting Group (BCG)
Isis Valle
Regulatory Inteligence for Innovation · Franklin da Costa Attorneys & Consultants
Jeffrey Speicher
Commercial General Manager · PLD Pharma Services
John Lowry
Chairman and CEO · Praxis Packaging Solutions
John Nosta
Founder · NostaLab
Julia Sable
Director Technical Partnerships and Portfolio Management · Kite Pharmaceuticals
Karen Greene
Partner · Network Partners Group
Karen Kozarsky
President/CSO · Vector BioPartners

— and 26 more, by name unsung —

§II

Underwritten By

The houses behind the program. Tiers as disclosed.
BD Advancing the world of health
Merck
NovartisWelcome & Reception Sponsor
Procaps Group
ThermoFisher Scientific
§III

The Programme

Selected from 8 sessions on the bill.
  • Jun 2, 2026, 10:00 AM to 11:30 AM

    Industry Power Hour, by the Sustainability Collective

    The complexity of the global pharma industry requires collaboration across the industry to drive sustainability efforts. In this fast-paced session, we will provide an overview of …

    Sustainability
  • Jun 2, 2026, 10:55 AM to 11:00 AM

    Opening Chair Remarks

    Opening chair remarks for the Track 1 - US Insights track.

    Track 1 - US Insights
  • Jun 2, 2026, 11:00 AM to 11:20 AM

    Inside the FDA: What’s Happening Now and What’s Coming Next?

    For more than two decades at the FDA, Dr. Richard Pazdur stood at the center of drug regulation as Director of the Center for Drug Evaluation and Research and the Oncology Center o…

    Track 1 - US Insights
  • Jun 2, 2026, 11:25 AM to 11:30 AM

    Innovation Stage Opening Remarks

    R&D and Drug Formulation Track
  • Jun 2, 2026, 11:25 AM to 11:50 AM

    Tariff Talk: Navigating Pharma's Forced Supply Chain Revolution

    The pharmaceutical industry faces its most dramatic supply chain restructuring in decades. With U.S. tariffs escalating from 100% to a threatened 250% on branded pharmaceuticals, t…

    Track 1 - US Insights
  • Jun 2, 2026, 9:15 AM to 9:45 AM

    From Globalization to Geoeconomics: U.S. Pharmaceutical Manufacturing in a New Reality

    For decades, U.S. pharmaceutical manufacturing operated within a globally optimized system built on scale, cost efficiency, technical capability, and regulatory alignment across ma…

    PLENARY SESSIONS
  • Jun 2, 2026, 9:50 AM to 10:35 AM

    The New Dynamics of U.S. Pharma: How Market Forces Are Redefining the Industry's Future

    The U.S. pharmaceutical industry is undergoing a pivotal transformation. Innovation in technology and therapeutics, evolving regulation, and shifting investment priorities are rede…

    PLENARY SESSIONS
  • June 3, 2026 (Day 2) 1:30 - 2:00pm

    John Nosta book signing

    Join us at CPHI Americas for a book signing with John Nosta, founder of NOSTALAB and author of The Borrowed Mind. A global innovation theorist and top tech influencer, John offers …

Intermission
Part the Second · For the Buyer

What does it mean when 58 companies show up — and 2 bet on three roles at once?

58 companies. two are betting more than once.

The numbers below are derived from the speakers, sponsors, and exhibitors on this page — cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.

01Fig. 01 — Composition of the House
2All threespeak · spons · exh
5Sponsoringsponsor only
9Exhibitingexhibitor only
42Companies Speakingspeaker only

The Triple-Threat

Adare Pharma Solutions·Pfizer

02Fig. 02 — The Voices, by Seniority

54% of the speakers carry senior titles — C-suite, Founder, VP, or Director-level.

  • C-suite715%
  • Founder / Owner36%
  • VP-level613%
  • Director / Head of1021%
  • Manager / Lead48%
  • Research / Science12%
  • Advisor / Investor12%
  • Other roles1633%

Of 48 on the bill · classified by free-text title

03Fig. 03 — The Heaviest in the Room
  1. 01Adare Pharma SolutionsEx1V
  2. 02BD Advancing the world of healthSp
  3. 03MerckSp
  4. 04NovartisSp·W
  5. 05PfizerEx1V
  6. 06Procaps GroupSp
  7. 07Thermo Fisher ScientificSp
  8. 08AlcamiEx
  9. 09Altasciences2V
  10. 10AsymchemEx
  11. 11BiophoreEx
  12. 12CambrexEx
  13. 13FrontageEx
  14. 14Network Partners Group2V
04Fig. 04 — By Tier
welcome & reception sponsor1
20% of 5
unspecified4
80% of 5
06Fig. 06 — Adjacent Convocations · by shared underwriters